Pharmacogenetic-guided prescribing of SSRIs

01 Oct 2026
Depression
01 Oct 2026

This randomized controlled trial investigated whether pharmacogenetic clinical guideline interventions of either a dose adjustment or switching to a different SSRI in the intervention group resulted in improved depression scores after 3 months compared to the control group. Individual variations in the speed at which CYP2D6 and CYP2C19 enzymes metabolise SSRIs are proposed to affect efficacy, but definitive evidence is still lacking. 

There was no significant difference in depression scores between the 2 groups after 3 months; however, at 6 months a significantly higher proportion of patients in the intervention arm had gone into remission. This suggests that future studies could focus on the longer-term impact of pharmacogenomic-guided prescribing of SSRIs.

Read more here.